Sponsors
The bill trades sizable, liquidity-friendly tax incentives to spur U.S. production of generic drugs and biosimilars — boosting domestic capacity, supply resilience, and potential lower prices — against reduced federal revenue, timing-driven investment uncertainty, eligibility exclusions, and added compliance burdens.
Manufacturers of eligible generic drugs and biosimilars in the U.S. (including small domestic producers) receive large tax incentives—value-added credits (30–35% plus domestic-content bonus) and a 25% credit for qualifying capital investments—together with elective refundable payment/transfer options, lowering upfront and operating costs and improving liquidity for investment and scale-up.
U.S. patients, hospitals, and rural communities see strengthened domestic drug production capacity and supply-chain resilience because the credits incentivize onshoring and increased manufacturing of generics and biosimilars.
Patients (especially those with chronic conditions) and health systems could benefit from greater availability of lower-cost generic drugs and biosimilars over time as domestic capacity expands.
The tax credits will reduce federal tax receipts, potentially increasing the deficit or creating pressure to raise revenue or cut spending elsewhere.
Time limits and phase-downs (construction and placed-in-service deadlines plus the credit phasedown ending after 2033) create investment uncertainty, may rush project timelines, and could exclude later-needed investments.
Firms with unresolved FDA warning letters are excluded from the credit, which can penalize companies that are remediating compliance problems and discourage investment by those recovering from past violations.
Based on analysis of 3 sections of legislative text.
Introduced May 22, 2025 by Thomas Bryant Cotton · Last progress May 22, 2025
Creates two new federal tax incentives to encourage domestic production of ingredients and final products for approved generic drugs and licensed biosimilars. One is a nonrefundable production tax credit tied to a taxpayer’s value added for producing eligible components (base 30%, 35% for final production, with a domestic-content bonus and a multi-year phaseout). The other is a 25% investment tax credit for qualified property placed in service at U.S. facilities that make those components. Both credits exclude certain foreign-controlled entities, block crediting for products from facilities with unresolved FDA warning letters, and include rules to prevent double-dipping between the production and investment credits. The production credit applies to eligible products produced after enactment; the investment credit applies to property placed in service after Dec 31, 2026 (construction must begin by Dec 31, 2028). Treasury is authorized to issue implementing regulations and guidance, and both credits are added to existing elective payment/transfer mechanisms in the tax code.